First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately...
Barchart Research What to Expect from TGTX Earnings TGTX Generated May 5, 2026 Current Price $36.10 EPS Estimate $$0.23 Consensus Rating Moderate Buy Average Move 12.28% TG Therapeutics Reports Tuesday...
- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association...
Barchart Research What to Expect from TGTX Earnings TGTX Generated May 1, 2026 Current Price $33.85 EPS Estimate $$0.23 Consensus Rating Moderate Buy Average Move 12.28% TG Therapeutics Consensus Appears...
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the...
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms...
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15,...
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (“TG” or “the Company”), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured...
- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - ...